The Chalcogen Is Bonded Directly To Two Carbon Atoms Patents (Class 514/239.2)
-
Publication number: 20140194427Abstract: Provided is a compound of formula (I): or a pharmaceutically acceptable salt thereof. Also provided is a method of treating, prophylaxis, or amelioration of a disease, comprising administering to a subject in need of treatment for the disease an effective amount of a compound of formula (I) described herein. In one embodiment, the method is a neurodegenerative disease, such as multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease, or Alzheimer's disease.Type: ApplicationFiled: March 7, 2014Publication date: July 10, 2014Applicant: Biogen IDEC MA Inc.Inventor: Jianhua CHAO
-
Patent number: 8765812Abstract: Substituted cinnamoyl anthranilate compounds exhibiting anti-fibrotic activity; or derivatives thereof, analogues thereof, pharmaceutically acceptable salts thereof, and metabolites thereof; with the proviso that the compound is not Tranilast.Type: GrantFiled: July 5, 2007Date of Patent: July 1, 2014Assignee: Fibrotech Therapeutics Pty LtdInventors: Spencer John Willams, David Stapleton, Steven Zammit, Darren James Kelly, Richard Ernest Gilbert, Henry Krum
-
Publication number: 20140178503Abstract: The present invention relates to new cyclohexyl urea modulators of D2 receptors and/or modulators of D3 receptors, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: February 26, 2014Publication date: June 26, 2014Applicant: Auspex Pharmaceuticals, Inc.Inventors: Ronald C. Newbold, Chengzhi Zhang
-
Publication number: 20140170196Abstract: The present invention provides disposable cloths that are designed to reduce itching discomfort when wiped across the vulvar tissue. These disposable cloths are wetted with a composition that includes at least one anesthetic, protectant, buffer, and surfactant. The composition is substantially clear and preferably does not bring about a cooling or stinging sensation when applied to the vulvar tissue. Furthermore, the composition has a pH adapted to vulvar use.Type: ApplicationFiled: December 19, 2012Publication date: June 19, 2014Inventors: Bobby Corry, Russ Hovda, Michael L. Caswell
-
Publication number: 20140120185Abstract: The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (I) a compound which is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracyclic antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination.Type: ApplicationFiled: April 4, 2012Publication date: May 1, 2014Inventors: Tsuyoshi Hirose, Kenji Maeda, Tetsuro Kikuchi, Masafumi Toda
-
Publication number: 20140065211Abstract: Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclosed.Type: ApplicationFiled: August 22, 2013Publication date: March 6, 2014Applicant: XenoPort, Inc.Inventors: Sami Karaborni, Sarina Grace Harris Ma, Chen Mao, Ching Wah Chong, Peter Robert Prinz Freed, Mesut Ciper, Stefanie Krenzlin, David J. Wustrow, Peter A. Virsik
-
Publication number: 20140057917Abstract: Methods of reducing undesirable side effects during therapeutic treatment using monomethyl fumarate and prodrugs of monomethyl fumarate are disclosed.Type: ApplicationFiled: August 22, 2013Publication date: February 27, 2014Applicant: XenoPort, Inc.Inventors: Kenneth C. Cundy, Sami Karaborni, Peter A. Virsik
-
Publication number: 20140056978Abstract: Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclosed.Type: ApplicationFiled: August 22, 2013Publication date: February 27, 2014Applicant: XenoPort, Inc.Inventors: Sami Karaborni, Laura Elizabeth Bauer, Chen Mao, Ching Wah Chong, David J. Wustrow, Peter A. Virsik
-
Publication number: 20140057918Abstract: Methods of therapeutic treatment using monomethyl fumarate and prodrugs of monomethyl fumarate are disclosed.Type: ApplicationFiled: August 22, 2013Publication date: February 27, 2014Applicant: XenoPort, Inc.Inventors: David J. Wustrow, Peter A. Virsik, Mark A. Gallop, Kenneth C. Cundy, Dmitri V. Lissin, Revati Shreeniwas
-
Publication number: 20140051705Abstract: Morpholinoalkyl fumarates, pharmaceutical compositions comprising the morpholinoalkyl fumarates, and methods of using morpholinoalkyl fumarates and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis are disclosed.Type: ApplicationFiled: August 14, 2013Publication date: February 20, 2014Applicant: XenoPort, Inc.Inventors: Kenneth C. Cundy, Suresh K. Manthati, David J. Wustrow
-
Patent number: 8641816Abstract: Provided are new functionalized surfactants and methods of their preparation and use. The surfactants are compounds of formula I: wherein R1, R2, and R3 are as defined herein.Type: GrantFiled: October 21, 2010Date of Patent: February 4, 2014Assignee: Dow Global Technologies LLCInventors: Matthias S. Ober, Edward D. Daugs, Wanglin Yu, Cynthia L. Rand
-
Publication number: 20140018366Abstract: Compositions for treating a condition associated with activity of a muscarinic receptor (e.g., one or more of M1, M2, M3, M4, M5) and for anesthetizing a subject include a bitopic muscarinic antagonist or agonist. A bitopic muscarinic antagonist named JB-D4 was discovered. This bitopic ligand and its structural analogs, as well as bitopic muscarinic agonists, may be used as neuromuscular blocking agents (e.g., for use in compositions for anesthetizing a subject) and for the treatment of central nervous system disorders (e.g., Parkinson's disease, Schizophrenia, etc.), Overactive Bladder Syndrome, Chronic Obstructive Pulmonary Disease, asthma, and many other diseases associated with the activation or inhibition of M1-M5 acetylcholine receptors.Type: ApplicationFiled: July 9, 2013Publication date: January 16, 2014Inventor: John BOULOS
-
Publication number: 20140018341Abstract: A method of inhibiting phosphorylation of the tau protein and/or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system an effective amount of a of a compound or a pharmaceutically acceptable salt thereof that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1, and contains at least four of the six pharmacophores of FIGS. 35-40.Type: ApplicationFiled: July 11, 2013Publication date: January 16, 2014Inventors: Hoau-Yan Wang, Lindsay Burns Barbier
-
Publication number: 20130315842Abstract: The present invention provides methods of administering an active agent to a localized mucous membrane in the oral cavity of a mammal, as well as oral dissolving film formed therefore.Type: ApplicationFiled: January 1, 2013Publication date: November 28, 2013Inventor: Andrew L. SKIGEN
-
Publication number: 20130310385Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient which is an antidepressant.Type: ApplicationFiled: May 13, 2013Publication date: November 21, 2013Applicant: GRUENENTHAL GMBHInventors: Stefanie FROSCH, Klaus LINZ, Thomas CHRISTOPH
-
Publication number: 20130310386Abstract: Methods for treating eye diseases associated with inflammation and/or vascular proliferation in subjects are disclosed. The methods include administering therapeutically effective amounts of a tranilast compound, in particular (E)-2-[[3-(3-Methoxy-4-propargyloxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or (E)-2-[[3,4-Bis(difluoromethoxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or pharmaceutically acceptable salts or solvates thereof.Type: ApplicationFiled: November 10, 2011Publication date: November 21, 2013Applicant: Fibrotech Therapeutics Pty LtdInventors: Darren James Kelly, David Stapleton
-
Patent number: 8580776Abstract: This invention provides agents, compositions, pharmaceutical compositions and methods for treating or slowing the progression of a neurodegenerating disease, such as Alzheimer's disease and a demyelinating disease.Type: GrantFiled: October 18, 2010Date of Patent: November 12, 2013Assignee: The Board of Trustees of the University of IllinoisInventors: Douglas L. Feinstein, Maria Vittoria Simonini, Sergey Kalinin, Paul E. Polak
-
Publication number: 20130296324Abstract: The invention relates generally to novel pharmaceutical methods for the treatment of various conditions. Compositions comprising: at least one phosphodiesterase-5-inhibitor in combination with one or more of the following medications: a selective serotonin reuptake inhibitor; a serotonin-norepinephrine reuptake inhibitor; a cholinesterase inhibitor; a dopamine agonist; or a medication suitable to increase the chemical concentrations of the neurotransmitters, selected from amino acids, monoamines, neuropeptides and other agents capable of primary neurotransmission in the synaptic clefts, and their use for treating a neurodegenerative disease in a subject. The invention also relates to: Compositions comprising: at least one phosphodiesterase-5-inhibitor in combination with one or more of the following medications: a selective serotonin reuptake inhibitor; or a cholinesterase inhibitor, and their use for treating damaged skin in a subject.Type: ApplicationFiled: February 25, 2013Publication date: November 7, 2013Applicant: VIVUS, Inc.Inventor: Jerry M. Held
-
Publication number: 20130289035Abstract: The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.Type: ApplicationFiled: June 28, 2013Publication date: October 31, 2013Inventor: Christopher D. Breder
-
Publication number: 20130245575Abstract: A composition and method for administering topical and external topical and external body products for prevention and treatment of anal/vaginal ailments, the composition comprising a mixture of a melting agent, a healing agent, a hardening agent a moisture barrier agent, a carrier agent, the mixture in solid state and undergoing a phase change to a lubricating state when applied to a human body.Type: ApplicationFiled: September 7, 2012Publication date: September 19, 2013Inventor: Sara Jo Griffin
-
Patent number: 8530471Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein B, Y, and A are as described. Methods, compositions, and medicaments related thereto are also disclosed.Type: GrantFiled: May 4, 2009Date of Patent: September 10, 2013Assignee: Allergan, Inc.Inventors: Yariv Donde, Jeremiah H. Nguyen
-
Publication number: 20130217681Abstract: Presented herein is a methodology for reducing weight in obese subjects and in patients receiving various medical treatments that are accompanied with weight gain. The methodology allows for management of weight gain, management of triglyceride levels and weight reduction in obese subjects.Type: ApplicationFiled: November 22, 2011Publication date: August 22, 2013Applicants: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD., RAMOT AT TEL-AVIV UNIVERSITY LTD.Inventors: Avraham Weizman, Michael Poyurovsky
-
Publication number: 20130209403Abstract: The invention relates to Phospholipase A2 (hereinafter also referred to as PLA2) inhibitors for use in the treatment or prevention of flavivirus infection, in particular an infection with a flavivirus of the genus Flavi or the genus Hepaci. The invention also provides a pharmaceutical formulation for use in the treatment or prevention of an infection with a flavivirus of the genus Flavi or the genus Hepaci and a method of preventing or treating an infection with a flavivirus of the genus Flavi or the genus Hepaci.Type: ApplicationFiled: September 8, 2011Publication date: August 15, 2013Applicants: Ruprecht-Karls-Universitaet, Twincore Zentrum fuer Experimentelle and Klinische Infektionsforschung GmbHInventors: Nicolas Menzel, Thomas Pietschmann, Ralf Bartenschlager, Wolfgang Fischl
-
Publication number: 20130202661Abstract: Modified release formulations of viloxazine and methods of administering the same are disclosed. High-drug load formulations of viloxazine are further disclosed.Type: ApplicationFiled: February 7, 2013Publication date: August 8, 2013Applicant: Supernus Pharmaceuticals, Inc.Inventor: Supernus Pharmaceuticals, Inc.
-
Publication number: 20130203727Abstract: The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds of formula (I).Type: ApplicationFiled: July 1, 2011Publication date: August 8, 2013Applicant: GILEAD SCIENCES, INC.Inventors: Kerim Babaoglu, Elizabeth Bacon, Kyla Bjornson, Hongyan Guo, Randall L. Halcomb, Paul Hrvatin, John O. Link, Hongtao Liu, Ryan McFadden, Michael L. Mitchell, Paul Roethle, James Taylor, James D. Trenkle, Randall W. Vivian, Lianhong Xu
-
Publication number: 20130203753Abstract: Morpholinoalkyl fumarates, pharmaceutical compositions comprising the morpholinoalkyl fumarates, and methods of using morpholinoalkyl fumarates and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis are disclosed.Type: ApplicationFiled: February 7, 2013Publication date: August 8, 2013Applicant: XENOPORT, INC.Inventor: XENOPORT, INC.
-
Publication number: 20130116227Abstract: Disclosed is a novel biaryl amide derivative represented by formula (1) and having an affinity for the aldosterone receptor; also disclosed is a pharmaceutically acceptable salt thereof. (In the formula, A is any of the groups represented by formula (a); L is —CONH—, etc.; R1 is a substitutable aminosulfonyl group, etc.; R2 is a hydrogen atom, etc.; R3 is a hydrogen atom, etc.; R4 is a hydrogen atom, a halogen atom, hydroxy group, a substitutable amino group, a substitutable C1-6 alkoxy group, a substitutable 4- to 7-membered cyclic amino group, etc.; R5a, R5b and R5c are each independently hydrogen atoms, etc.; R6 is a halogen atom, a cyano group, etc.; R7 and R8 are each independently a hydrogen atom, etc.; and m is an integer such as 0.Type: ApplicationFiled: July 12, 2011Publication date: May 9, 2013Applicant: DAINIPPON SUMITOMO PHARMA CO., LTD.Inventors: Seiji Katayama, Seiji Hori, Futoshi Hasegawa, Kuniko Suzuki
-
Publication number: 20130109674Abstract: The present invention relates to, among other things, methods for treating trigeminal cephalgias such as migraine and migraine like headaches and other cerebrovascular conditions associated with pain and or inflammation. When non-steroidal anti inflammatory drugs (NSAIDs), such as ketoprofen, are applied locally using specific topical formulations immediate relief of pain is obtained. Intense pain is typically reduced to mild pain or no pain within 30 minutes of application of the topical formulation. The NSAID may be given in combination with other pharmacological agents, such as vasoconstrictors, opioids, decongestants and/or non-opioid migraine drugs, such as triptans and ergots and agents that affect serotonin receptors as agonists, antagonists or partial agonists.Type: ApplicationFiled: December 17, 2010Publication date: May 2, 2013Applicant: Achelios Therapeutics LLCInventors: Harry J. Leighton, Matthew J. Buderer, Crist J. Frangakis
-
Publication number: 20130071450Abstract: The present disclosure provides hydrogels that are suitable for drug delivery. In embodiments, hydrogels of the present disclosure may be used for transdermal delivery of bioactive agents, including drugs. The hydrogels of the present disclosure may also be useful as conductive compositions for use with electrodes.Type: ApplicationFiled: November 15, 2012Publication date: March 21, 2013Applicant: COVIDIEN LPInventor: Covidien LP
-
Publication number: 20130045978Abstract: The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.Type: ApplicationFiled: June 22, 2012Publication date: February 21, 2013Inventors: R. Scott Bitner, Kaitlin E. Browman, Michael E. Brune, Steven Fung, Peer B. Jacobson, Lynne E. Rueter, Marina I. Strakhova, Jiahong Wang, Jyoti R. Patel, Qi Shuai, James T. Link, Jeffrey J. Rohde, Jurgen Dinges, Bryan K. Sorensen, Martin Winn, Hong Yong, Vince S. Yeh
-
Publication number: 20130023535Abstract: The present invention relates to an agent for preventing and/or treating diabetic neuropathy comprising a 2-[(substituted-inden-7-yloxy)methyl]morpholine of the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. The invention is useful for providing an excellent agent for preventing and/or treating diabetic neuropathy, and particularly useful for providing an agent for preventing and/or treating diabetic motor neuropathy (such as muscle weakness disorder (such as muscle weakness disorder with inability to walk independently)), diabetic sensory neuropathy (such as paresthesia (such as vibration perception abnormality), allodynia, hypoesthesia (such as numbness of extremities or cold sensation), or pain), or diabetic autonomic neuropathy (such as stool abnormality (such as constipation or diarrhea), urination disorder, impotence, orthostatic hypotension, sudomotor dysfunction, abnormal heart rate variability, or delayed gastric emptying).Type: ApplicationFiled: August 23, 2012Publication date: January 24, 2013Applicant: Astellas Pharma Inc.Inventors: TOSHIAKI AOKI, NOBUHITO MURAI, SEIJI TAMURA, HIROKO YAMAMOTO, NOZOMU HAMAKAWA
-
Publication number: 20120329781Abstract: The instant invention relates to a combination, particularly a synergistic combination, of an alpha-2-delta ligand and a dual serotonin-noradrenaline re-uptake inhibitor (DSNRI) or one or both of a selective serotonin re-uptake inhibitor (SSRI) and a selective noradrenaline re-uptake inhibitor (SNRI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof and their use in the treatment of pain, particularly neuropathic pain.Type: ApplicationFiled: August 29, 2012Publication date: December 27, 2012Inventors: David James Dooley, Mark John Field, Richard Griffith Williams
-
Publication number: 20120264757Abstract: The invention provides an oil-in-water emulsion useful in the treatment of anorectal disorders comprising a local anesthetic, vasoconstrictor, glycerin and water, and method of preparation of the emulsion and a method for treating hemorrhoids using the composition of the invention.Type: ApplicationFiled: June 29, 2012Publication date: October 18, 2012Applicant: WyethInventors: Gary Robert Agisim, Richard John Kenny, Miron Gerard Still, Ellen Bland Gilliam, Helen Elizabeth Taylor
-
Patent number: 8258133Abstract: A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administration. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative represented by formula [I] [wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR3R4 or the like (wherein R3 and R4 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.Type: GrantFiled: October 7, 2011Date of Patent: September 4, 2012Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Akito Yasuhara, Kazunari Sakagami, Hiroshi Ohta, Atsuro Nakazato
-
Patent number: 8252308Abstract: The present invention provides a substantially clear gel designed to reduce itching discomfort when applied to the vulvar tissue. The gel includes at least one anesthetic, protectant, emulsifier, and pH modifier, such as a base. The gel has a pH adapted to vulvar use and may be applied to the vulvar tissues.Type: GrantFiled: January 27, 2005Date of Patent: August 28, 2012Assignee: C.B. Fleet Company Inc.Inventors: Nelson Ayala, Michael L. Caswell
-
Publication number: 20120213869Abstract: A pain relieving composition that includes an anesthetic in the range of 0.5%-7.0% by weight (“w/w”), an anti-inflammatory agent in the range of 1.0%-11.0% w/w, a moisturizing agent in the range of 0.5%-12.0% w/w, a humescent in the range of 0.5%-13.0% w/w, a penetration enhancing agent in the range of 0.5%-7.0%, and a carrier solvent in the range of 40.0%-97.0% w/w to be used before and/or after procedures which cause damage to human skin.Type: ApplicationFiled: February 23, 2011Publication date: August 23, 2012Applicant: MISS SMARTY PANTS ENTERPRISES, INC.Inventor: Edna Ma
-
Patent number: 8242103Abstract: Bridged bicyclic sulphamides of formula (I) are disclosed for treatment of cancer.Type: GrantFiled: May 16, 2006Date of Patent: August 14, 2012Assignee: Merck Sharp & Dohme LimitedInventors: Huw David Lewis, Timothy Harrison, Mark Steven Shearman
-
Patent number: 8202513Abstract: The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.Type: GrantFiled: October 3, 2008Date of Patent: June 19, 2012Assignee: Bionomics LimitedInventors: Bernard Luke Flynn, Jonathan Bayldon Baell, Jason Hugh Chaplin, Gurmit Singh Gill, Damian Wojciech Grobelny, Andrew John Harvey, Jorgen Alvar Mould, Dharam Paul
-
Publication number: 20120149707Abstract: The present invention relates to an alpha-arylmethoxyacrylate derivative, a preparation method thereof and a pharmaceutical composition comprising the same, and the alpha-arylmethoxyacrylate derivative is inhibitory of HIF, which plays an important role in the regulation of genes associated with energy metabolism, vasomotion, angiogenesis and apoptosis and in the response of cells under hypoxic conditions, so that it can be used for preventing or treating of diseases such as cancer, arthritis, psoriasis, diabetic retinopathy and macular degeneration.Type: ApplicationFiled: April 21, 2011Publication date: June 14, 2012Applicant: OSCOTEC INC.Inventors: Se-Won Kim, Jung Ho Kim, Se-Nyum Kim, Dae-Pil Kang, Youn Ho Han, Guo Fan Jin, Dong-Sik Jung, Sung-Ho Park, Ji Min Kim, Jhi Zheng
-
Publication number: 20120148520Abstract: The present inventions relate to a number of fields including wound healing, a waterless antibacterial disinfectant, a surgical scrub, insect repellant, and methods of treating traumatic injuries, particularly those on the battlefield where there is a need to stabilize the patient and prevent infection.Type: ApplicationFiled: December 9, 2011Publication date: June 14, 2012Inventors: Michael Strobel, Gene Komer
-
Publication number: 20120115862Abstract: The present invention relates to compounds of the formula I wherein R1, R2, R3, R4, X and Y have the meanings given in the description. The compounds have an action which is immunomodulating and inhibits or regulates the release of IL-1? and/or TNF-?. They can therefore be used for treatment of diseases connected with a disturbance in the immune system.Type: ApplicationFiled: October 9, 2009Publication date: May 10, 2012Inventors: Stefan Laufer, Wolfgang Albrecht
-
Publication number: 20120115871Abstract: The invention comprises a method of treatment of depression or depression-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.Type: ApplicationFiled: April 29, 2010Publication date: May 10, 2012Inventor: Christopher D. Breder
-
Publication number: 20120070507Abstract: Provided herein are compositions and methods for the treatment of soft tissue injury, sports-related injury, physical overuse of muscles, ligaments or joints, and trauma, traumatic stress or sudden jolts on bones and tissues in an individual. Described herein are pharmaceutical compositions comprising a vasoconstrictor and, optionally, a topical analgesic and methods of using said compositions for the treatment of a variety of soft tissue injuries.Type: ApplicationFiled: September 17, 2010Publication date: March 22, 2012Applicant: MATRILINEX LLCInventors: Corinna HOWELL, Neil HOWELL
-
Publication number: 20120046247Abstract: This invention relates to compounds of Formula (I), (II), or (III) as shown in the specification, which contain a 1,5-diphenylpenta-1,4-dien-3-one backbone. These compounds can be used to treat cancer, inflammatory disease, or autoimmune disease.Type: ApplicationFiled: August 16, 2011Publication date: February 23, 2012Inventors: Charles C-Y Shih, Toshio Kitamura, Qian Shi, Toshiyuki Kawashima, Hui-Kang Wang
-
Publication number: 20120028982Abstract: A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administration. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative represented by formula [I] [wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR3R4 or the like (wherein R3 and R4 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.Type: ApplicationFiled: October 7, 2011Publication date: February 2, 2012Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Akito YASUHARA, Kazunari Sakagami, Hiroshi Ohta, Atsuro Nakazato
-
Patent number: 8106033Abstract: Methods and compositions are provided for treating proliferative disorders, wherein the composition comprises at least one compound according to Formula I: wherein R1 is selected from the group consisting of —OH, —NH2, —NH—CH2—CO2H, —NH—CH(CH3)—CO2H, and —NH—C(CH3)2—CO2H, or a pharmaceutically acceptable salt of such a compound; and an anthracycline, e.g. doxorubicin, or a pharmaceutically acceptable salt thereof, or a platin, e.g. oxaliplatin, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 10, 2006Date of Patent: January 31, 2012Assignees: Temple University - Of The Commonwealth System of Higher Education, Mount Sinai School of MedicineInventors: E. Premkumar Reddy, James F. Holland
-
Publication number: 20120004232Abstract: A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administration A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative represented by formula [I] [wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR3R4 or the like (wherein R3 and R4 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.Type: ApplicationFiled: September 8, 2011Publication date: January 5, 2012Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Akito YASUHARA, Kazunari SAKAGAMI, Hiroshi OHTA, Atsuro NAKAZATO
-
Patent number: 8076333Abstract: The present invention relates to pharmaceutical compositions containing Naratriptan, a compound selected from the group consisting of 2-HPOD, 2-HPHM, 4-PPED, 4-BPED and 2-PPED, and optionally, a pharmaceutically acceptable excipient.Type: GrantFiled: March 31, 2009Date of Patent: December 13, 2011Assignee: Emisphere Technologies Inc.Inventor: Cristina Castelli
-
Publication number: 20110301105Abstract: We have discovered that p63 inhibition results in increased cellular proliferation. We have also performed a screen for agents capable of increasing cellular proliferation, (e.g., of stem cells such as skin-derived precursors (SKPs)). The invention therefore invention provides compositions, methods, and kits for increasing proliferation of cells, using compounds that decrease p63 expression or activity or using the compounds described herein. The invention also features methods of using these compounds for increasing hair growth, improving skin health, or promoting skin repair in a subject.Type: ApplicationFiled: March 30, 2011Publication date: December 8, 2011Applicant: The Hospital for Sick ChildrenInventors: Freda Miller, David Kaplan, Kristen Smith, Maryline Paris, Sibel Naska
-
Publication number: 20110281844Abstract: Use of a compound of formula (A), wherein: W is a residue which imparts antagonistic and/or agonistic activity at histamine H3-receptors when attached to an imidazole ring in 4(5) position; R1 and R2 may be identical or different and represent each independently a lower alkyl or cycloalkyl, or taken together with the nitrogen atom to which they are attached, a saturated nitrogen-containing ring (i) as defined, a non-aromatic unsaturated nitrogen-containing ring (ii) as defined, a morpholino group, or a N-substituted piperazino group as defined for preparing medicaments acting as antagonists and/or agonists at the H3-receptors of histamine.Type: ApplicationFiled: December 15, 2010Publication date: November 17, 2011Inventors: Jean-Charles SCHWARTZ, Jean-Michel ARRANG, Monique GARBARG, Jeanne-Marie LECOMTE, Xavier LIGNEAU, Walter G. SCHUNACK, Holger STARK, Charon Robin GANELLIN, Fabien LEURQUIN, Elz Sigurd